ConforMIS (CFMS) Earning Somewhat Favorable News Coverage, Accern Reports

News headlines about ConforMIS (NASDAQ:CFMS) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ConforMIS earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned headlines about the medical instruments supplier an impact score of 45.3673020755747 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news headlines that may have effected Accern’s scoring:

Shares of ConforMIS (NASDAQ CFMS) traded down $0.04 during trading on Friday, reaching $2.50. The company had a trading volume of 248,662 shares, compared to its average volume of 594,074. ConforMIS has a fifty-two week low of $2.43 and a fifty-two week high of $9.47. The company has a current ratio of 6.19, a quick ratio of 5.38 and a debt-to-equity ratio of 0.52.

ConforMIS (NASDAQ:CFMS) last announced its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported ($0.29) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.03. ConforMIS had a negative return on equity of 76.88% and a negative net margin of 72.70%. The business had revenue of $18.40 million for the quarter, compared to analysts’ expectations of $17.55 million. During the same period in the previous year, the business posted ($0.31) EPS. The firm’s quarterly revenue was down 1.3% compared to the same quarter last year. sell-side analysts forecast that ConforMIS will post -1.27 EPS for the current year.

A number of research firms have recently commented on CFMS. ValuEngine upgraded ConforMIS from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Zacks Investment Research cut ConforMIS from a “buy” rating to a “hold” rating in a research note on Tuesday, October 31st. Finally, BTIG Research reiterated a “hold” rating on shares of ConforMIS in a research note on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. ConforMIS has an average rating of “Hold” and a consensus price target of $5.85.

In related news, CTO Daniel Steines sold 15,485 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $3.15, for a total value of $48,777.75. Following the sale, the chief technology officer now directly owns 254,652 shares in the company, valued at approximately $802,153.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David Cerveny sold 16,392 shares of the business’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $3.17, for a total value of $51,962.64. Following the completion of the sale, the insider now owns 151,408 shares in the company, valued at $479,963.36. The disclosure for this sale can be found here. Insiders sold a total of 56,535 shares of company stock worth $177,824 over the last 90 days. 9.55% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “ConforMIS (CFMS) Earning Somewhat Favorable News Coverage, Accern Reports” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/09/conformis-cfms-earning-somewhat-favorable-news-coverage-accern-reports.html.

About ConforMIS

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Insider Buying and Selling by Quarter for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply